The first clinical trial to directly compare Adventrx Pharmaceuticals Inc.'s CoFactor (ANX-510) to leucovorin missed its primary endpoint of reducing serious hematological or gastrointestinal adverse events associated with the chemotherapy drug 5-fluorouracil (5-FU).(BioWorld Today) Read More
